The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability
Yi, Shou-pu1; Kong, Qing-hong1; Li, Yu-lei2; Pan, Chen-ling1; Yu, Jie1; Cui, Ben-qiang1; Wang, Ying-fei1; Wang, Guan-lin1; Zhou, Pei-lan2; Wang, Li-li3; Gong, Ze-hui2; Su, Rui-bin2; Shen, Yue-hai1,4; Yu, Gang2; Chang, Kwen-jen1
2017-07-01
发表期刊ACTA PHARMACOLOGICA SINICA
卷号38期号:7页码:977-989
关键词Opioid Receptor Mixed Agonist Dpi-125 Analgesia Respiratory Depression Addiction
收录类别SCI ; SSCI ; SSCI
语种英语
引用统计
文献类型期刊论文
条目标识符http://ir.kib.ac.cn/handle/151853/54826
专题植物化学与西部植物资源持续利用国家重点实验室
作者单位1.Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming 650500, Peoples R China
2.Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China
3.Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China
4.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming 650201, Peoples R China
推荐引用方式
GB/T 7714
Yi, Shou-pu,Kong, Qing-hong,Li, Yu-lei,et al. The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability[J]. ACTA PHARMACOLOGICA SINICA,2017,38(7):977-989.
APA Yi, Shou-pu.,Kong, Qing-hong.,Li, Yu-lei.,Pan, Chen-ling.,Yu, Jie.,...&Chang, Kwen-jen.(2017).The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.ACTA PHARMACOLOGICA SINICA,38(7),977-989.
MLA Yi, Shou-pu,et al."The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability".ACTA PHARMACOLOGICA SINICA 38.7(2017):977-989.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
yi2017.pdf(854KB)期刊论文作者接受稿开放获取CC BY-NC-SA请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yi, Shou-pu]的文章
[Kong, Qing-hong]的文章
[Li, Yu-lei]的文章
百度学术
百度学术中相似的文章
[Yi, Shou-pu]的文章
[Kong, Qing-hong]的文章
[Li, Yu-lei]的文章
必应学术
必应学术中相似的文章
[Yi, Shou-pu]的文章
[Kong, Qing-hong]的文章
[Li, Yu-lei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。